I-Mab has been granted a patent for anti-GM-CSF antibodies and fragments for therapeutic, diagnostic, and prognostic purposes. The method involves administering specific antibodies to inhibit inflammatory cytokine production in human subjects, targeting GM-CSF proteins. GlobalData’s report on I-Mab gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights I-Mab - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on I-Mab, Personalized cancer vaccines was a key innovation area identified from patents. I-Mab's grant share as of April 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-gm-csf antibodies for treating inflammatory diseases

Source: United States Patent and Trademark Office (USPTO). Credit: I-Mab

A recently granted patent (Publication Number: US11926662B2) discloses a method for inhibiting the production of inflammatory cytokines in human subjects by administering an antibody or antigen-binding fragment targeting the human granulocyte macrophage colony-stimulating factor (GM-CSF) protein. The specificity of the antibody is defined by the amino acid sequences of the VH and VL regions, including specific complementarity determining regions (CDRs) outlined in the patent claims.

The method outlined in the patent targets inflammatory cytokines such as TNF, IL-6, IL-12p70, IL-23, IL-1ß, and their combinations in subjects in need, particularly those suffering from infections. The antibody or fragment administered may also include heavy and light chain constant regions, Fc regions, or a combination thereof. Additionally, the patent specifies the humanization of the antibody and provides a range of amino acid sequences for the VH and VL regions that can be utilized in the method. This patent highlights a novel approach to modulating inflammatory responses in human subjects through the targeted inhibition of GM-CSF protein.

To know more about GlobalData’s detailed insights on I-Mab, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies